Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adabepilimab
- Development stage
- Phase 3
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Adabepilimab is a humanized monoclonal antibody designed to act as an immune checkpoint inhibitor by targeting the programmed cell death protein 1 (PD-1) receptor. Developed by Hansoh Pharmaceutical, it is intended to restore T-cell mediated anti-tumor activity by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Adabepilimab is currently being evaluated in late-stage clinical trials, particularly in combination with other oncology agents such as the B7-H3-targeting antibody-drug conjugate HS-20093. Its primary development focus is on advanced solid tumors, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), where it is being tested as part of combination regimens to improve outcomes in patients who have progressed on prior therapies.
- Other names
- adabepilimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on adabepilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adabepilimab.